Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2023-08-03 00:00:00 ET · period of report 2023-08-02 · accession 0001140361-23-037942 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-03 | 2023-08-02 | ROIV | Gline Matthew | CEO, Dir | J - Other | $11.79 | -11.7K | 1.05M | -1% | -$138.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-08-02 | J | D | 11,749 | $11.79 | 1,050,659 | D | — | — | (F2) The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.79 to $11.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |